Post-Marketing Surveillance of Lenvima in Korean Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02764554

Enrollment

132

Registered

2016-05-06

Start date

2016-11-10

Completion date

2021-09-29

Last updated

2021-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Differentiated Thyroid Carcinoma (DTC)

Keywords

Post-Marketing Surveillance, Lenvima, Lenvatinib, E7080, Differentiated thyroid carcinoma, Refractory to radioactive iodine, Progressive, locally recurrent, metastatic

Brief summary

The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Participants who meet the following criteria will be eligible for inclusion in the study: 1. Participants with approved indication for lenvatinib in Korea 2. Participants who have written consent for use of personal and medical information for the study purpose

Exclusion criteria

Investigators will refer to approved indications and contraindications regarding

Design outcomes

Primary

Measure	Time frame
Number of Participants with Adverse Events, Serious Adverse Events, and Adverse Drug Reactions	Up to 1 year

Countries

South Korea

Outcome results